Forced degradation studies: current trends and future perspectives for protein-based therapeutics

References

• ICH Q1A (R2). Stability testing of new drug substances and products. Fed Regis. 2003;68(225):65717–65718.
   PubMedGoogle Scholar
• ICH Q5C. Quality of biotechnological products: stability testing of biotechnological/biological products. Fed Regis. 1996;61:36466–36474.
   Google Scholar
• Hasija M, Li L, Rahman N, et al. Forced degradation studies: an essential tool for the formulation development of vaccines. Vaccine. 2013;3:11–33.
   Google Scholar
• Hawe A, Wiggenhorn M, van de Weert M, et al. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101:895–913.
   PubMed Web of Science ®Google Scholar
• EBE concept paper. Forced degradation studies for therapeutic proteins. 2015. Available from: www.ebe-biopharma.eu
   Google Scholar
• Tamizi E, Jouyban A. Forced degradation studies of biopharmaceuticals: selection of stress conditions. Eur J Pharm Biopharm. 2016;98:26–46.
   PubMed Web of Science ®Google Scholar
• Chan CP. Biochemical and biophysical methods currently used for therapeutic protein development. Am Pharm Rev. 2008;11(7):24–32.
   Google Scholar
• Berkowitz SA, Engen JR, Mazzeo JR, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11:527–540.
   PubMed Web of Science ®Google Scholar
• Liu H, Ponniah G, Zhang HM, et al. In vitro and in vivo modifications of recombinant and human IgG antibodies. mAbs. 2014;6(5):1145–1154.
   PubMed Web of Science ®Google Scholar
• Goetze AM, Schenauer MR, Flynn GC. Assessing monoclonal antibody product quality attribute criticality through clinical studies. mAbs. 2010;2(5):500–507.
   PubMed Web of Science ®Google Scholar
• Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544–575.
   PubMed Web of Science ®Google Scholar
• Liu D, Ren D, Huang H, et al. Structure and stability of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 2008;47:5088–5100.
   PubMed Web of Science ®Google Scholar
• Temel DB, Landsman P, Brader ML. Orthogonal methods for characterizing the unfolding of therapeutic monoclonal antibodies: differential scanning calorimetry, isothermal chemical denaturation, and intrinsic fluorescence with concomitant static light scattering. Methods Enzymol. 2016;567:359–389.
   PubMed Web of Science ®Google Scholar
• Zhou C, Qi W, Lewis EN, et al. Concomitant Raman spectroscopy and dynamic light scattering for characterization of therapeutic proteins at high concentrations. Anal Biochem. 2015;472:7–20.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Luo Q, Nashed-Samuel Y, et al. Classification and characterization of therapeutic antibody aggregates. J Biol Chem. 2011;286:25118–25133.
   PubMed Web of Science ®Google Scholar
• Luo Q, Joubert MK, Stevenson R, et al. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem. 2011;286:25134–25144.
   PubMed Web of Science ®Google Scholar
• Wang W, Roberts CJ. Non-Arrhenius protein aggregation. AAPS J. 2013;15:840–851.
   PubMed Web of Science ®Google Scholar
• Salija A, Badkar AV, Zeng DL, et al. Ultrasonic rheology of a monoclonal antibody (IgG2) solution: implications for physical stability of proteins in high concentration formulations. J Pharm Sci. 2007;96:3181–3195.
   PubMed Web of Science ®Google Scholar
• Roberts CJ, Nesta DP, Kim N. Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody. J Pharm Sci. 2013;102:3556–3566.
   PubMed Web of Science ®Google Scholar
• Pace AL, Wong RL, Zhang YT, et al. Asparagine deamidation dependence on buffer type, pH, and temperature. J Pharm Sci. 2013;102:1712–1723.
   PubMed Web of Science ®Google Scholar
• Ji JA, Zhang B, Cheng W, et al. Trytophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization. J Pharm Sci. 2009;98:4485–4500.
   PubMed Web of Science ®Google Scholar
• Torosantucci R, Schoneich C, Jiskoot W. Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res. 2014;31:541–553.
   PubMed Web of Science ®Google Scholar
• Kerwin BA, Remmele RL. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96:1468–1479.
   PubMed Web of Science ®Google Scholar
• Khor HK, Jacoby ME, Suier TC, et al. Identification of methionine sulfoxide diastereomers in immunoglobulin gamma antibodies using methionine sulfoxide reductase enzymes. mAbs. 2010;2(3):299–308.
   PubMed Web of Science ®Google Scholar
• Amano M, Kobayashi N, Yabuta M, et al. Detection of histidine oxidation in a monoclonal immunoglobulin gamma (IgG) antibody. Anal Chem. 2014;86:7536–7543.
   PubMed Web of Science ®Google Scholar
• ICH Q1B. Stability testing: photostability testing of new drug substances and products. Fed Regis. 1997;62(95):27115–27122.
   Google Scholar
• Mason BD, Schoneich C, Kerwin BA. Effect of pH and light on aggregation and conformation of an IgG1 mAb. Mol Pharm. 2012;9:774–790.
   PubMed Web of Science ®Google Scholar
• Kiese S, Pappenberger A, Friess W, et al. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci. 2008;97:4347–4366.
   PubMed Web of Science ®Google Scholar
• Randolph TW, Schiltz E, Sederstrom D, et al. Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation. J Pharm Sci. 2015;104:602–611.
   PubMed Web of Science ®Google Scholar
• Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12:505–523.
   PubMed Web of Science ®Google Scholar
• Lorenze T, Fiaux J, Heitmann D, et al. Developability assessment of biologics by integrated biologics profiling [Internet]. Amer Pharma Rev. [cited 2014 Aug 29]. Available from: http://www.americanpharmaceuticalreview.com/Featured-Articles/167439-Developability-Assessment-of-Biologics-by-Integrated-Biologics-Profiling/
   Google Scholar
• Li Y, Mach H, Blue JT. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. J Pharm Sci. 2011;100:2120–2135.
   PubMed Web of Science ®Google Scholar
• Haberger M, Bomans K, Diepold K, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies. Susceptibility vs. functionality of critical quality attributes. mAbs. 2014;6(2):327–339.
   PubMed Web of Science ®Google Scholar
• Wang W, Vlasak J, Li Y, et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immun. 2011;48:860–866.
   PubMed Web of Science ®Google Scholar
• Cordes AA, Carpenter JF, Randolph TW. Accelerated stability studies of abatacept formulations: comparison of freeze-thawing and agitation-induced stresses. J Pharm Sci. 2012;101:2307–2315.
   PubMed Web of Science ®Google Scholar
• Telikepalli SN, Kumru OS, Kalonia C, et al. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J Pharm Sci. 2014;103:796–809.
   PubMed Web of Science ®Google Scholar
• Filipe V, Jiskoot W, Basmeleh AH, et al. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. mAbs. 2012;4(6):740–752.
   PubMed Web of Science ®Google Scholar
• Telikepalli S, Shinogle HE, Thapa PS, et al. Physical characterization and in vitro biological impact of highly aggregated antibodies separated in size-enriched populations by fluorescence-activated cell sorting. J Pharm Sci. 2015;104:1575–1591.
   PubMed Web of Science ®Google Scholar
• Thiagarajan G, Widjaja E, Heo JH, et al. Use of Raman and Raman optical activity for the structural characterization of a therapeutic monoclonal antibody formulation subjected to heat stress. J Raman Spectrosc. 2015;46:531–536.
   Web of Science ®Google Scholar
• Maity H, Lai Y, Srivastava A, et al. Principles and applications of selective biophysical methods for characterization and comparability assessment of a monoclonal antibody. Curr Pharm Biotechnol. 2012;13:2078–2101.
   PubMed Web of Science ®Google Scholar
• Majumdar R, Middaugh CR, Weis DD, et al. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies. J Pharm Sci. 2015;104:327–345.
   PubMed Web of Science ®Google Scholar
• Moorthy BS, Schultz SG, Kim SG, et al. Predicting protein aggregation during storage in lyophilized solids using solid state amide hydrogen/deuterium exchange with mass spectrometric analysis. Mol Pharm. 2014;11:1869–1879.
   PubMed Web of Science ®Google Scholar
• Houde D, Berkowitz SA, Engen JR. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J Pharm Sci. 2011;100:2071–2086.
   PubMed Web of Science ®Google Scholar
• Konermann L, Stocks BB, Pan Y, et al. Mass spectrometry combined with oxidative labeling for exploring protein structure and folding. Mass Spectrom Rev. 2010;29:651–667.
   PubMed Web of Science ®Google Scholar
• Kaur P, Tomechko SE, Kiselar J, et al. Characterizing monoclonal antibody structure by carboxyl group footprinting. mAbs. 2015;7(3):540–552.
   PubMed Web of Science ®Google Scholar
• Kalonia C, Kumru OS, Prajapati I, et al. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data. J Pharm Sci. 2015;104:536–547.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Modis Y, High K, et al. Disassembly and reassembly of human papillomavirus virus-like particles produces virion-like antibody reactivity. Virol J. 2012;9:52.
   PubMed Web of Science ®Google Scholar
• Davies M, Wang G, Fu G, et al. mAb higher order structure analysis with protein conformational array ELISA. Br J Pharm Res. 2015;7(6):401–412.
   Google Scholar
• Naik S, Kumru OS, Cullom M, et al. Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometry. Protein Sci. 2014;23:1461–1478.
   PubMed Web of Science ®Google Scholar
• Cicerone MT, Pikal MJ, Qian KK. Stabilization of proteins in solid form. Adv Drug Deliv Rev. 2015;93:14–24.
   PubMed Web of Science ®Google Scholar
• ICH Q5E. Comparability of biotechnological/biological products subject to changes in their manufacturing process. Federal Register 2005;70(125):37861–37862.
   Google Scholar
• Chow SC. Challenging issues in assessing analytical similarity in biosimilar studies. Biosimilars. 2015;5:33–39.
   Google Scholar
• Teska BM, Li C, Winn BC, et al. Comparison of quantitative spectral similarity analysis methods for protein higher-order structure confirmation. Anal Biochem. 2013;434:153–165.
   PubMed Web of Science ®Google Scholar
• Burdick RK, Sidor L. Establishment of an equivalence acceptance criterion for accelerated stability studies. J Biopharm Stat. 2013;23:730–743.
   PubMed Web of Science ®Google Scholar
• Schofield TL. Maintenance of vaccine stability through annual stability and comparability studies. Biologicals. 2009;37:397–402.
   PubMed Web of Science ®Google Scholar
• Gao SX, Zhang Y, Stansberry-Perkins K, et al. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol Prog. 2011;108:977–982.
   Google Scholar
• Bee JS, Tie L, Johnson D, et al. Trace levels of the CHO host cell protease cathepsin D cause particle formation in a monoclonal antibody product. Biotechnol Prog. 2015;31:1360–1369.
   PubMed Web of Science ®Google Scholar
• Wang W, Ignatius AA, Thakkar SV. Impact of residual impurities and contaminants on protein stability. J Pharm Sci. 2014;103:1315–1330.
   PubMed Web of Science ®Google Scholar
• Kerwin BA. Polysorbate 20 and 80 used in the formulation for protein biotherapeutics: structure and degradation pathways. J Pharm Sci. 2008;97:2924–2935.
   PubMed Web of Science ®Google Scholar
• Siska CC, Pierini CJ, Lau HR, et al. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material. J Pharm Sci. 2015;104:447–456.
   PubMed Web of Science ®Google Scholar
• Labrenz SR. Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations. J Pharm Sci. 2014;103:2268–2277.
   PubMed Web of Science ®Google Scholar
• ICH Q8(R2). Pharmaceutical development [Internet]. 2009. [cited 2009 Nov 19]. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073507.pdf
   Google Scholar
• Haberger M, Heidenreich AK, Schlothauer T, et al. Functional assessment of antibody oxidation by native mass spectrometry. mAbs. 2015;7(5):891–900.
   PubMed Web of Science ®Google Scholar
• Alsenaidy MA, Jain NK, Kim JH, et al. Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles. Front Pharmacol. 2014;5:1–19.
   PubMed Web of Science ®Google Scholar